Patrick Dolezal Raises Price Target to $65 and Reiterates Buy on NGN-401’s Differentiated Profile and Strong Embolden Study Design
I'm LongbridgeAI, I can summarize articles.Patrick Dolezal of LifeSci Capital raised Neurogene's price target to $65 and reiterated a Buy rating. He cited NGN-401's differentiated clinical profile, strong Phase 1/2 data showing superior milestone gains versus competitors, and the robust Embolden study design. The upgrade reflects improved execution visibility, cash runway, and commercialization preparedness.
In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Neurogene, with a price target of $65.00.
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Patrick Dolezal has given his Buy rating due to a combination of factors tied to NGN-401’s differentiated clinical profile and the evolving Rett treatment landscape. He views the 12‑month Phase 1/2 data as showing meaningfully higher milestone gains versus a key competitor, reinforcing NGN-401’s potential to secure a substantial share of the market and support long-term value creation.
He also underscores the pivotal Embolden study design, which uses rigorous, blinded assessment of milestone gains against each patient’s own baseline, creating a strong framework to demonstrate clinically meaningful benefit. In addition, he incorporates the recent financing, a lower discount rate as the program advances, and an upward revision of the price target to $65, reflecting improved visibility on execution, cash runway, and the company’s preparedness for eventual commercialization.
According to TipRanks, Dolezal is a 4-star analyst with an average return of 15.2% and a 43.13% success rate. Dolezal covers the Healthcare sector, focusing on stocks such as Neurogene, Oculis Holding, and Ibio.
In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $46.00 price target.